Clinical trials: African Americans
Oral Health, Child
Testing Preliminary Effectiveness of a Training to Support CHWs Outreach on Dental to African American Caregivers
Two arm study, experimental and control, to explore the impact of an online training program to help community health workers conduct effective outreach to support the dental health of African American youth via their caregivers.
- Conditions
- Oral Health, Child, Adolescents, Self Efficacy
- Trial name
- GRIN (NCT05511935)
- Testing
- professional development training for CHWs on dental health (GRIN)
- Where
- United States
- Volunteers
- 143 people, healthy volunteers welcome
- Sponsor
- KDH Research & Communication
Triple Negative Breast Cancer, TNBC - Triple-Negative Breast Cancer
Study of CB-839 in Combination w/ Paclitaxel in Participants of African Ancestry and Non-African Ancestry With Advanced Triple Negative Breast Cancer (TNBC)
CX-839-007 is an open-label Phase 2 study of the combination of CB-839 with paclitaxel in participants of African ancestry and non-African ancestry with advanced triple negative breast cancer.
- Trial name
- NCT03057600
- Testing
- Paclitaxel, CB-839
- Where
- 25 sites in United States
- Volunteers
- 52 people
- Sponsor
- Calithera Biosciences, Inc
Hepatitis B Infection
Effect of Entecavir in Blacks/African Americans and Hispanics With Chronic Hepatitis B Virus (HBV) Infection
The purpose of this clinical research study is to develop observational clinical experience with the use of entecavir in participants who are either of Black/African-American race or of Hispanic ethnicity.
- Trial name
- NCT00371150
- Testing
- Entecavir
- Where
- 27 sites in United States, Brazil and 3 more
- Volunteers
- 131 people
- Sponsor
- Bristol-Myers Squibb
Asthma
Phase4/Symbicort® Versus Pulmicort Flexhaler® in African Americans
To compare the efficacy of SYMBICORT® pMDI 160/4.5 μg x 2 actuations twice daily (bid) to that of budesonide inhalation powder DPI 180 μg x 2 inhalations bid, in African American(self-reported) subjects with inhaled…
- Trial name
- Titan (NCT00702325)
- Testing
- Budesonide / formoterol fumarate (SYMBICORT), Budesonide
- Where
- 57 sites in United States
- Volunteers
- 311 people
- Sponsor
- AstraZeneca
Heart Failure (HF)
A Study of Ivabradine in African-American/ Black Subjects With Heart Failure and Left Ventricular Systolic Dysfunction.
This study is a prospective, open-label, single-arm intervention study in African-American/Black subjects with heart failure and reduced ejection fraction (HFrEF).
- Trial name
- NCT03456856
- Testing
- Ivabradine
- Where
- 3 sites in United States
- Volunteers
- 30 people
- Sponsor
- Amgen
Hepatitis C
Alisporivir (Deb025) and Boceprevir Triple Therapies in African American Participants Not Previously Treated for Chronic Hepatitis C Genotype 1
This study will assess the safety and efficacy of alisporivir (ALV) and boceprevir (BOC), each in combination with Peginterferon alfa-2a (PEG) and Ribavirin (RBV), in African American participants who have never received…
- Trial name
- NCT01446250
- Testing
- Alisporivir, Boceprevir, Peginterferon alfa-2a
- Where
- 2 sites in United States
- Volunteers
- 8 people
- Sponsor
- Debiopharm International SA
Caregiver Burnout
Testing Preliminary Effectiveness of a Community Health Worker (CHW) Training Program on Caregiving
Two arm study, experimental and control, to explore the impact of an online training program to prepare community health workers (CHWs) conduct effective outreach to support African American and Latino male caregivers of older…
- Trial name
- IN-HOME (NCT06049043)
- Testing
- Intervention to Help Orient Men to Excel (IN-HOME), AARP's English "Care at Home" resource webpage
- Where
- United States
- Volunteers
- 107 people, healthy volunteers welcome
- Sponsor
- KDH Research & Communication
Hypotrichosis
Study of Bimatoprost Solution in Increasing Eyelash Prominence in African Americans With Eyelash Hypotrichosis
This study will evaluate the safety and efficacy of bimatoprost solution 0.03% once daily to the upper eyelid margins (where the eyelashes meet the skin) compared with vehicle in increasing overall eyelash prominence in…
- Trial name
- NCT00958035
- Testing
- bimatoprost ophthalmic 0.03% solution
- Where
- United States
- Volunteers
- 89 people
- Sponsor
- Allergan
Healthy Subjects
THE EFFECT OF CYP3A5 GENOTYPE ON THE PHARMACOKINETICS OF MARAVIROC
This will be an open-label, parallel group, multiple dose study in approximately 48 healthy male or female subjects of African American and Caucasian self-reported race, to assess the effect of CYP3A5 genotype on the PK of MVC…
- Trial name
- NCT02625207
- Testing
- Maraviroc (Part 1), Maraviroc (Part 2), Darunavir/cobicistat (Part 2)
- Where
- United States
- Volunteers
- 47 people, healthy volunteers welcome
- Sponsor
- ViiV Healthcare
Hypertension
Efficacy and Safety of Azilsartan Medoxomil in African American Participants With Essential Hypertension
The purpose of this study is to evaluate the effectiveness and safety of azilsartan medoxomil compared to placebo, once daily (QD), in African-American participants with essential hypertension.
- Trial name
- NCT00591253
- Testing
- Azilsartan medoxomil
- Where
- 64 sites in United States, Puerto Rico
- Volunteers
- 413 people
- Sponsor
- Takeda
Diabetes Mellitus, Type 2
Efficacy and Safety of Linagliptin (BI 1356) in Black/African Americans With Type 2 Diabetes With a MTT Sub-study
Study of linagliptin vs. placebo in Black/African American patients with T2DM with a MTT sub-study
- Trial name
- NCT01194830
- Testing
- Linagliptin
- Where
- 93 sites in United States
- Volunteers
- 234 people
- Sponsor
- Boehringer Ingelheim
Systemic Lupus Erythematosus
Efficacy and Safety of Belimumab in Black Race Patients With Systemic Lupus Erythematosus (SLE)
The purpose of this study is to evaluate the efficacy, safety, and tolerability of belimumab in adult patients of black race with systemic lupus erythematosus (SLE; lupus).
- Trial name
- EMBRACE (NCT01632241)
- Testing
- Belimumab 10 mg/kg plus standard therapy, Standard therapy
- Where
- 96 sites in United States, Brazil and 4 more
- Volunteers
- 503 people
- Sponsor
- Human Genome Sciences Inc., a GSK Company
Hypertension
Efficacy and Safety of Aliskiren Administered in Combination With Amlodipine Versus Amlodipine Alone in African American Patients With Stage 2 Hypertension
The purpose of the study is to evaluate the BP-lowering efficacy of the combination of aliskiren and amlodipine, as initial therapy, compared to amlodipine monotherapy in African American patients with Stage II hypertension.
- Trial name
- AACESS (NCT00853957)
- Testing
- Aliskiren/Amlodipine, Amlodipine
- Where
- 9 sites in United States
- Volunteers
- 443 people
- Sponsor
- Novartis
Asthma
A Comparison of SYMBICORT® pMDI With Budesonide HFA pMDI in African American Subjects With Asthma.
The purpose of this study is to determine the effectiveness and safety of SYMBICORT® pMDI (a medication approved by the Food and Drug Administration, FDA) in the African American population.
- Trial name
- NCT00419952
- Testing
- Budesonide/formoterol (SYMBICORT) pMDI, Budesonide HFA pMDI
- Where
- 122 sites in United States
- Volunteers
- 742 people
- Sponsor
- AstraZeneca
Hypertension
Blood Pressure Lowering of Aliskiren Hydrochlorothiazide (HCTZ) Versus Amlodipine in Stage 2 Hypertension in African Americans
The purpose of the study is to evaluate the efficacy and safety of a fixed dose combination of aliskiren HCTZ versus amlodipine in African American patients with Stage 2 hypertension.
- Trial name
- ATLAAST (NCT00739596)
- Testing
- Aliskiren Hydrochlorothiazide (HCTZ): 8 weeks, Amlodipine: 8 weeks
- Where
- United States
- Volunteers
- 332 people
- Sponsor
- Novartis Pharmaceuticals
Stable Coronary Artery Disease
A Pharmacodynamic Study With Ticagrelor in African American Patients
The purpose of this study is to assess the pharmacodynamic effect of ticagrelor in African American patients with stable coronary artery disease.
- Trial name
- NCT01523392
- Testing
- Ticagrelor, Clopidogrel
- Where
- 8 sites in United States
- Volunteers
- 50 people
- Sponsor
- AstraZeneca
Diabetes Mellitus, Type 2, Hypertension
24 Week Efficacy and Safety Study of Empagliflozin (BI 10773) in Hypertensive Black/African American Patients With Type 2 Diabetes Mellitus and Hypertension
This trial is designed to investigate the efficacy and safety of empagliflozin compared with placebo in hypertensive black/African Americans with type 2 Diabetes Mellitus.
- Trial name
- NCT02182830
- Testing
- Empagliflozin low dose, Empagliflozin high dose
- Where
- 92 sites in United States
- Volunteers
- 166 people
- Sponsor
- Boehringer Ingelheim
Hepatitis C
BMS-790052 (Daclatasvir) Plus Peg-Interferon Alfa-2a and Ribavirin in Treatment-Naive Black/African-Americans, Latinos and White/Caucasians With Hepatitis C
The purpose of this study is to compare the rates of sustained virologic response in each cohort (Black-African Americans, Latinos) in this study to historical rate.
- Trial name
- NCT01389323
- Testing
- Daclatasvir, Peg-Interferon Alfa-2a, Ribavirin
- Where
- 36 sites in United States, Puerto Rico
- Volunteers
- 448 people
- Sponsor
- Bristol-Myers Squibb
HIV-1 Infection
Study to Evaluate Switching From a Regimen of Two Nucleos(t)Ide Reverse Transcriptase Inhibitors (NRTI) Plus a Third Agent to a Fixed Dose Combination (FDC) of Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF), in Virologically-Suppressed, HIV-1 Infected African American Participants
The primary objective of this study is to evaluate the efficacy of switching from a regimen of 2 nucleos(t)Ide reverse transcriptase inhibitors (NRTIs) and a third agent to a fixed dose combination (FDC) of…
- Trial name
- BRAAVE 2020 (NCT03631732)
- Testing
- B/F/TAF, NRTIs, Third Agent
- Where
- 82 sites in United States
- Volunteers
- 496 people
- Sponsor
- Gilead Sciences
Diabetes Mellitus, Type 2
Pharmacokinetics and Pharmacodynamics Trial With Linagliptin (BI 1356) 5mg in African American Type 2 Diabetic Patients
The objective of this trial is to investigate the pharmacokinetics and pharmacodynamics of linagliptin (BI 1356) 5 mg administered orally in patients with Type 2 diabetes mellitus of African American origin.
- Trial name
- NCT00935220
- Testing
- linagliptin QD (once daily) for 7 days
- Where
- 6 sites in United States
- Volunteers
- 41 people
- Sponsor
- Boehringer Ingelheim